Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$1.07M$1.07M−61.3% vs Q2 2025 Net Income$1.48M$1.48MN/M vs Q2 2025 EPS Diluted-$0.03-$0.03N/M vs Q2 2025 Operating Income-$8,923,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,352,000N/M Margins · derivedOperating margin-834.7%−119.3 pt vs Q2 2025
Net margin138.6%+1240.4 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end